Technical Analysis for SLRN - Acelyrin Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| Gapped Up | Strength | -7.38% | |
| Up 3 Days in a Row | Strength | -7.38% | |
| Boomer Sell Setup | Bearish Swing Setup | -7.19% | |
| Earnings Movers | Other | -7.19% | |
| Gapped Up | Strength | -7.19% | |
| 1,2,3 Retracement Bearish | Bearish Swing Setup | -6.40% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -6.40% | |
| Earnings Movers | Other | -6.40% | |
| Inside Day | Range Contraction | -6.40% |
| Alert | Time |
|---|---|
| Down 5% | 3 days ago |
| Possible NR7 | 3 days ago |
| 60 Minute Opening Range Breakdown | 3 days ago |
| Down 3% | 3 days ago |
| Fell Below 20 DMA | 3 days ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/13/2024
Acelyrin Inc. Description
ACELYRIN, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Medicine Drugs Monoclonal Antibodies Uveitis Psoriatic Arthritis Hidradenitis Suppurativa Thyroid Eye Disease Chronic Urticaria Duligotuzumab
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 29.88 |
| 52 Week Low | 4.14 |
| Average Volume | 1,241,601 |
| 200-Day Moving Average | 10.14 |
| 50-Day Moving Average | 5.81 |
| 20-Day Moving Average | 4.51 |
| 10-Day Moving Average | 4.65 |
| Average True Range | 0.33 |
| RSI (14) | 33.77 |
| ADX | 31.69 |
| +DI | 12.76 |
| -DI | 21.95 |
| Chandelier Exit (Long, 3 ATRs) | 4.18 |
| Chandelier Exit (Short, 3 ATRs) | 5.13 |
| Upper Bollinger Bands | 4.97 |
| Lower Bollinger Band | 4.06 |
| Percent B (%b) | 0.36 |
| BandWidth | 20.16 |
| MACD Line | -0.29 |
| MACD Signal Line | -0.39 |
| MACD Histogram | 0.102 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.86 | ||||
| Resistance 3 (R3) | 4.90 | 4.79 | 4.78 | ||
| Resistance 2 (R2) | 4.79 | 4.67 | 4.77 | 4.75 | |
| Resistance 1 (R1) | 4.59 | 4.60 | 4.54 | 4.55 | 4.73 |
| Pivot Point | 4.48 | 4.48 | 4.45 | 4.46 | 4.48 |
| Support 1 (S1) | 4.28 | 4.36 | 4.23 | 4.24 | 4.05 |
| Support 2 (S2) | 4.17 | 4.29 | 4.15 | 4.03 | |
| Support 3 (S3) | 3.97 | 4.17 | 4.00 | ||
| Support 4 (S4) | 3.93 |
